Seroprevalence of SARS-CoV-2 antibodies in patients with hematological and oncological diseases in early 2024
The data presented confirm broad variations in SARS-CoV-2 anti-spike IgG levels across patients with different hematological and oncological diseases and highlight the complex interference of cancer biology, immune dysfunction, and treatment-related factors in shaping immune responses. Further research is needed to elucidate the mechanisms underlying these variations in antibody levels. We emphasize the need for regular booster vaccinations in this patient group.
Authors
- Lutz Gieselmann (ORCID: https://orcid.org/0000-0003-3699-3318)
- Henning Gruell (ORCID: https://orcid.org/0000-0002-0725-7138)
- Veronica Di Cristanziano (ORCID: https://orcid.org/0000-0003-1604-8386)
- Jannik Stemler (ORCID: https://orcid.org/0000-0001-9152-2469)
- Rosanne Sprute (ORCID: https://orcid.org/0000-0003-2457-6437)
- Jon Salmanton‐García (ORCID: https://orcid.org/0000-0002-6766-8297)
- Oliver A. Cornely (ORCID: https://orcid.org/0000-0001-9599-3137)
- Sibylle C. Mellinghoff (ORCID: https://orcid.org/0000-0003-3928-2503)
- Louise Cremer (ORCID: https://orcid.org/0009-0002-1425-7352)
- Sebastian Herrmann
- Theresa Markus
Institutions
- University of Cologne (DE)
- Düsseldorf University Hospital (DE)
- Integrated Oncology (United States) (US)
- German Center for Infection Research (DE)
- Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE)
- University Hospital Cologne (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- Blood Research
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1007/s44313-025-00067-5
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitätsklinikum Köln